Houston, TX - August 21st, 2025- OmniScience, the company behind Vivo, the first agentic AI control tower for clinical trials, received acceptance into the 2025 DayOne Accelerator, a globally recognized program dedicated to transforming healthcare through innovation in pharma and clinical R&D.

Run by Basel-based DayOne the accelerator focuses on startups solving high-impact challenges.

OmniScience was selected as one of just 15 companies from more than 200 global applicants, following a rigorous review and interview process.

Participation in the DayOne Accelerator will provide OmniScience with direct access to pharma executives, expert coaching, and strategic guidance to expand its footprint and impact within the global clinical research ecosystem. The program includes a live kickoff event in Basel in September, a three-month virtual accelerator, and a final Innovation Showcase in December, connecting the cohort with industry leaders and investors.

“We’re honored to be selected for DayOne’s HealthTech x Pharma R&D cohort,” said Angela Holmes, CEO and Co-Founder of OmniScience. “This recognition affirms both our mission and the global relevance of Vivo. Clinical trials are the gatekeeper for every medical innovation, and we’re building AI that accelerates them and makes them smarter, more transparent, and more successful. We’re excited to collaborate with leading pharma teams through DayOne and bring transformative technology to trial teams so they can get new treatments to patients who need it most.”

OmniScience’s flagship product, Vivo, is already in use across biotech and pharma organizations to reduce trial timelines, cut manual effort by up to 70%, and improve probability of success. With auditability, real-time insights, and intelligent agent workflows, Vivo is setting a new standard for clinical trial operations.